How Investors Are Reacting To Revvity (RVTY) and Sanofi's Collaboration on Early Type 1 Diabetes Detection

• On October 2, 2025, Sanofi announced a collaboration supporting Revvity in expanding its type 1 diabetes (T1D) offering with the development of a new 4-plex in vitro diagnostic assay for early detection, aiming for global clinical use and major regulatory submissions.
• This move positions Revvity to broaden patient access and elevate population-scale screening for early-stage T1D, addressing a worldwide need with significant implications for patient outcomes and standard of care.
• We’ll now explore how this partnership to advance early T1D detection could influence Revvity’s long-term growth outlook and investment case.

These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Revvity Investment Narrative Recap

To be a shareholder in Revvity, you need to believe in the company’s ability to drive meaningful innovation in diagnostics and scale life science solutions globally, especially as precision medicine and early detection become bigger priorities for healthcare systems. The recent Sanofi collaboration supports Revvity’s efforts to expand its population-scale diagnostics, but it does not change the most important near-term catalyst, which remains the accelerated adoption of higher-growth software and consumables. The biggest short-term risk continues to be margin and volume pressure from regulatory changes in China. The impact of this new T1D initiative on near-term financials is not expected to be immediately material, though it does show Revvity’s ambition to broaden global clinical reach and tackle unmet medical needs. The most relevant recent announcement to this news event is Revvity’s strategic partnership with Profluent to accelerate the Pin-point™ base editing platform using AI-driven tools for greater precision in gene editing. Like the Sanofi alliance, this showcases Revvity’s focus on applying advanced science for real-world clinical and research impact, aligning with broader business catalysts, such as the shift to higher-margin, software-enabled platforms and consumables that can support sustainable growth. In contrast, investors should also be aware that China’s reimbursement and regulatory changes could pressure diagnostic margins and volumes sooner than expected, especially as...

Read the full narrative on Revvity (it's free!)

Revvity's narrative projects $3.3 billion revenue and $599.9 million earnings by 2028. This requires 5.4% yearly revenue growth and a $321.2 million earnings increase from $278.7 million today.

Uncover how Revvity's forecasts yield a $115.19 fair value, a 27% upside to its current price.

Exploring Other Perspectives

Community members at Simply Wall St estimate Revvity’s fair value between US$115.19 and US$134.45, reflecting two distinct outlooks. Regulatory and cost-containment risks in China remain a key factor as you consider these varying perspectives on future performance.

Explore 2 other fair value estimates on Revvity - why the stock might be worth as much as 48% more than the current price!

Build Your Own Revvity Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Revvity research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Revvity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Revvity's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• The end of cancer? These 28 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com